(Q39413582)

English

Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis

scientific article published on 12 January 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Reingard Senekowitsch-Schmidtke

5

object named as

Reingard Senekowitsch-Schmidtke

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

8

object named as

Christof Seidl

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Frank Bruchertseifer

6

object named as

Frank Bruchertseifer

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Alfred Morgenstern

7

object named as

Alfred Morgenstern

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1

object named as

Markus Essler

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Florian C Gärtner

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Frauke Neff

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Birgit Blechert

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

12 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

602-612

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Tumor therapy with targeted atomic nanogenerators

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Cyclotron production of Ac-225 for targeted alpha therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Targeted radiotherapy with radiolabeled somatostatin analogs

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Radiometallated peptides for molecular imaging and targeted therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Current Concepts and Future Directions in Radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Cancer radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Radioimmunotherapy of Solid Tumors: Searching for the Right Target

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Efforts to control the errant products of a targeted in vivo generator

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2023-6

21 January 2018

Production of Ac-225 from Th-229 for targeted alpha therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22237842

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-011-2023-6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39413582&oldid=2202858002"